{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T06:50:08Z","timestamp":1744786208750,"version":"3.37.3"},"reference-count":20,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2018,2,19]],"date-time":"2018-02-19T00:00:00Z","timestamp":1518998400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Genes Chromosomes &amp; Cancer"],"published-print":{"date-parts":[[2018,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Chromosome abnormalities detected during cytogenetic investigations for B\u2010cell malignancy offer prognostic information that can have wide ranging clinical impacts on patients. These impacts may include monitoring frequency, treatment type, and disease staging level. The use of the synthetic oligonucleotide DSP30 combined with interleukin 2 (IL2) has been described as an effective mitotic stimulant in B\u2010cell disorders, not only in chronic lymphocytic leukemia (CLL) but also in a range of other B\u2010cell malignancies. Here, we describe the comparison of two B\u2010cell mitogens, lipopolysaccharide (LPS), and DSP30 combined with IL2 as mitogens in a range of common B\u2010cell disorders excluding CLL. The results showed that DSP30\/IL2 was an effective mitogen in mature B\u2010cell disorders, revealing abnormal cytogenetic results in a range of B\u2010cell malignancies. The abnormality rate increased when compared to the use of LPS to 64% (DSP30\/IL2) from 14% (LPS). In a number of cases the disease burden was proportionally very low, less than 10% of white cells. In 37% of these cases, the DSP30 culture revealed abnormal results. Importantly, we also obtained abnormal conventional cytogenetics results in 3 bone marrow cases in which immunophenotyping showed an absence of an abnormal B\u2010cell clone. In these cases, the cytogenetics results correlated with the provisional diagnosis and altered their staging level. The use of DSP30 and IL2 is recommended for use in many B\u2010cell malignancies as an effective mitogen and their use has been shown to enable successful culture of the malignant clone, even at very low levels of disease.<\/jats:p>","DOI":"10.1002\/gcc.22527","type":"journal-article","created":{"date-parts":[[2018,1,19]],"date-time":"2018-01-19T05:42:49Z","timestamp":1516340569000},"page":"260-267","source":"Crossref","is-referenced-by-count":3,"title":["DSP30 and interleukin\u20102 as a mitotic stimulant in B\u2010cell disorders including those with a low disease burden"],"prefix":"10.1002","volume":"57","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1191-8939","authenticated-orcid":false,"given":"Karen A.","family":"Dun","sequence":"first","affiliation":[{"name":"Cytogenetics Laboratory Royal Hobart Hospital  Tasmania Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Louise A.","family":"Riley","sequence":"additional","affiliation":[{"name":"Cytogenetics Laboratory Royal Hobart Hospital  Tasmania Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Diano","sequence":"additional","affiliation":[{"name":"Cytogenetics Laboratory Royal Hobart Hospital  Tasmania Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leanne B.","family":"Adams","sequence":"additional","affiliation":[{"name":"Cytogenetics Laboratory Royal Hobart Hospital  Tasmania Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eleanor","family":"Chiu","sequence":"additional","affiliation":[{"name":"Cytogenetics Laboratory Royal Hobart Hospital  Tasmania Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Archna","family":"Sharma","sequence":"additional","affiliation":[{"name":"Department of Haematology Royal Hobart Hospital  Tasmania Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2018,2,19]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-02-005322"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/gcc.22293"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1309\/AJCP7G4VMYZJQVFI"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1468-0734.2000.00003.x"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.2353\/jmoldx.2009.080101"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-61779-074-4_8"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1159\/isbn.978-3-318-05979-3"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21357"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428190701836845"},{"key":"e_1_2_6_11_1","first-page":"417","article-title":"Deletions linked to TP53 loss drive cancer through P53\u2010independent mechanisms","volume":"24","author":"Liu Y","year":"2016","journal-title":"Nature."},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2011.056176"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1097\/GIM.0b013e3181f8baad"},{"key":"e_1_2_6_14_1","first-page":"244","article-title":"Mantle cell lymphoma management and outcome in the U.K's population\u2010based haematological malignancy research network","volume":"33","author":"Patmore R","year":"2015","journal-title":"Haemat Oncol."},{"key":"e_1_2_6_15_1","doi-asserted-by":"crossref","first-page":"4773","DOI":"10.1182\/blood.V128.22.4773.4773","article-title":"Characterization of real world treatment patterns and outcomes among older adults with chronic lymphocytic leukemia in the pre novel\u2010agents era: an analysis of the 2007\u20132013 SEER\u2010Medicare database","volume":"128","author":"Mato AR","year":"2016","journal-title":"Blood."},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmoldx.2014.03.006"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.5858\/arpa.2016-0527-OA"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2008.252"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1159\/000369543"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-014-1681-0"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cancergencyto.2010.07.128"}],"container-title":["Genes, Chromosomes and Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fgcc.22527","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/gcc.22527","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,26]],"date-time":"2023-09-26T03:22:07Z","timestamp":1695698527000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/gcc.22527"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,19]]},"references-count":20,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["10.1002\/gcc.22527"],"URL":"https:\/\/doi.org\/10.1002\/gcc.22527","archive":["Portico"],"relation":{},"ISSN":["1045-2257","1098-2264"],"issn-type":[{"type":"print","value":"1045-2257"},{"type":"electronic","value":"1098-2264"}],"subject":[],"published":{"date-parts":[[2018,2,19]]}}}